Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers

Inclusion Criteria: Subjects could be included in the study if they met the following criteria: * Healthy male or female volunteers * Written informed consent in accordance with Good Clinical Practice (GCP) and the local legislation prior to admission to the study * Age 21 - 50 years * Body mass index (BMI): 18.5 - 29.9 kg/m2 Exclusion Criteria: Subjects were not allowed to participate if any of the following applied: * Any finding of the medical examination (including blood pressure, pulse rate, Respiratory rate, body temperature and ECG) deviating from normal and of clinical relevance * Raw \> 3 cm H2O • s • L-1 or FEV1 \<80% of predicted * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system, psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts, * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\>24 hours) within at least 1 month or less than 10 half-lives of the respective drug before enrolment in the study * Use of any drugs which might influence the results of the trial (within 1 week prior to administration of investigational drug or during the trial) * Participation in another trial with an investigational drug (within 2 months prior to drug administration or during the trial) * Smoker (\>10 cigarettes/day or \>3 cigars/day or \>3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\>60 gram/day) * Drug abuse * Blood donation (≥100 mL within 4 weeks prior to administration of investigational drug or during the trial) * Excessive physical activities (within the last week before the study) * Any laboratory value outside the reference range and of clinical relevance * For female subjects: * Pregnancy * Positive pregnancy test * No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device * Inability to maintain this adequate contraception during the whole study period, * Lactation period